

Swiss Biotech Success Stories award winner 2021

Bachem



BACHEM

Bachem is a leading manufacturer of peptides and oligonucleotides. The company has grown over 50% in the last five years and now offers more than 5,500 different biologically active peptides amino acid derivatives and oligonucleotides. Its investment plans call for the investment of over USD 400M to continue to pursue its growth strategy.

Bachem is a leading, innovation-driven company in the development and manufacture of peptides and oligonucleotides.

With 50 years of expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide, and offers a comprehensive range of services.

Founded in 1971 as Bachem Feinchemikalien AG in Liestal, near Basel, the company's initial focus was on amino acid and peptide synthesis. From this original business idea, Bachem grew to the world's leading company in the development and production of peptides and oligonucleotides: a success story based on courage, innovation, quality, partnership and exceptional people. The company is strongly committed to sustainability, and takes a responsible attitude towards its employees, society, and the environment.

Long-term growth has always been a key measurement of success at Bachem, as was made clear when founder and Honorary Chairman, Dr. h.c. Peter Grogg took the company public on the Swiss Stock Exchange in 1998. Today, Bachem is supporting pharma and biotech companies in ~ 150 NCE peptide projects in different clinical development phases. It has expanded its portfolio by establishing itself as a full-service

provider for the development of oligonucleotides. The company also innovates and excels in the development and manufacture of peptides and complex organic molecules, offering more than 5,500 different biologically active peptides, amino acid derivatives, and biochemicals in its stock catalog.

With headquarters in Switzerland and operations in Europe, the US and Asia, Bachem has a global reach. A research and development facility was recently opened in Bubendorf, and over the past five years Bachem AG has grown by more than 50% - it now employs over 1,000 people across its sites at Bubendorf & Vionnaz in Switzerland. In 2018, a sales office was opened in Tokyo, Japan, to drive business in the Asian market and strengthen customer support. With investment plans for over USD 400M in the next five years, the Bachem Group will continue to pursue its ambitious growth strategy.